{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T02:21:55Z","timestamp":1781662915264,"version":"3.54.5"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2015,1,8]],"date-time":"2015-01-08T00:00:00Z","timestamp":1420675200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"published-print":{"date-parts":[[2015,4]]},"DOI":"10.1007\/s10557-014-6565-2","type":"journal-article","created":{"date-parts":[[2015,1,7]],"date-time":"2015-01-07T01:00:47Z","timestamp":1420592447000},"page":"179-185","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Rationale and Design of the Double-Blind, Randomized, Placebo-Controlled Multicenter Trial on Efficacy of Early Initiation of Eplerenone Treatment in Patients with Acute Heart Failure (EARLIER)"],"prefix":"10.1007","volume":"29","author":[{"name":"on behalf of the EARLIER investigators and study coordinators","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori","family":"Asakura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruko","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuniya","family":"Asai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihisa","family":"Hanatani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken-ichi","family":"Hirata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Hirayakma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuo","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youichi","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin-ichi","family":"Momomura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihisa","family":"Nakagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaro","family":"Nishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiko","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Satoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahisa","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Yamashina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Yasuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsutomu","family":"Yoshikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiko","family":"Kada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Uesaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masafumi","family":"Kitakaze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,1,8]]},"reference":[{"key":"6565_CR1","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.amjcard.2013.10.032","volume":"113","author":"PP Chang","year":"2014","unstructured":"Chang PP, Chambless LE, Shahar E, et al. Incidence and survival of hospitalized acute decompensated heart failure in four US communities (from the atherosclerosis risk in communities study). Am J Cardiol. 2014;113:504\u201310.","journal-title":"Am J Cardiol"},{"key":"6565_CR2","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1253\/circj.CJ-66-0068","volume":"77","author":"Guidelines for treatment of acute heart failure (JCS 2011)","year":"2013","unstructured":"Guidelines for treatment of acute heart failure (JCS 2011). Cir J: Off J Jpn Circ Soc. 2013;77:2157\u2013201.","journal-title":"Cir J: Off J Jpn Circ Soc"},{"key":"6565_CR3","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1093\/eurjhf\/hfs033","volume":"14","author":"JJ McMurray","year":"2012","unstructured":"McMurray JJ, Adamopoulos S, Anker SD, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the European society of cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2012;14:803\u201369.","journal-title":"Eur J Heart Fail"},{"key":"6565_CR4","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1016\/j.ijcard.2012.10.007","volume":"167","author":"RJ Mentz","year":"2013","unstructured":"Mentz RJ, Bakris GL, Waeber B, et al. The past, present and future of renin-angiotensin aldosterone system inhibition. Int J Cardiol. 2013;167:1677\u201387.","journal-title":"Int J Cardiol"},{"key":"6565_CR5","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.jacc.2011.03.057","volume":"58","author":"CM O\u2019Connor","year":"2011","unstructured":"O\u2019Connor CM, Fiuzat M, Swedberg K, et al. Influence of global region on outcomes in heart failure beta-blocker trials. J Am Coll Cardiol. 2011;58:915\u201322.","journal-title":"J Am Coll Cardiol"},{"key":"6565_CR6","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s10741-005-6127-6","volume":"9","author":"GC Fonarow","year":"2004","unstructured":"Fonarow GC, Corday E. Overview of acutely decompensated congestive heart failure (ADHF): a report from the ADHERE registry. Heart Fail Rev. 2004;9:179\u201385.","journal-title":"Heart Fail Rev"},{"key":"6565_CR7","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1253\/circj.CJ-13-0187","volume":"77","author":"N Sato","year":"2013","unstructured":"Sato N, Kajimoto K, Keida T, et al. Clinical features and outcome in hospitalized heart failure in Japan (from the ATTEND registry). Circ J: Off J Jpn Circ Soc. 2013;77:944\u201351.","journal-title":"Circ J: Off J Jpn Circ Soc"},{"key":"6565_CR8","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","volume":"341","author":"B Pitt","year":"1999","unstructured":"Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized aldactone evaluation study investigators. N Engl J Med. 1999;341:709\u201317.","journal-title":"N Engl J Med"},{"key":"6565_CR9","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","volume":"348","author":"B Pitt","year":"2003","unstructured":"Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309\u201321.","journal-title":"N Engl J Med"},{"key":"6565_CR10","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1093\/eurjhf\/hft100","volume":"15","author":"N Girerd","year":"2013","unstructured":"Girerd N, Pang PS, Swedberg K, et al. Serum aldosterone is associated with mortality and re-hospitalization in patients with reduced ejection fraction hospitalized for acute heart failure: analysis from the EVEREST trial. Eur J Heart Fail. 2013;15:1228\u201335.","journal-title":"Eur J Heart Fail"},{"key":"6565_CR11","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s10741-011-9280-0","volume":"17","author":"M Gheorghiade","year":"2012","unstructured":"Gheorghiade M, Pang PS, Ambrosy AP, et al. A comprehensive, longitudinal description of the in-hospital and post-discharge clinical, laboratory, and neurohormonal course of patients with heart failure who die or are re-hospitalized within 90\u00a0days: analysis from the EVEREST trial. Heart Fail Rev. 2012;17:485\u2013509.","journal-title":"Heart Fail Rev"},{"key":"6565_CR12","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","volume":"364","author":"F Zannad","year":"2011","unstructured":"Zannad F, McMurray JJ, Krum H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364:11\u201321.","journal-title":"N Engl J Med"},{"key":"6565_CR13","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1093\/eurjhf\/hfr093","volume":"13","author":"JJ McMurray","year":"2011","unstructured":"McMurray JJ. CONSENSUS to EMPHASIS: the overwhelming evidence which makes blockade of the renin-angiotensin-aldosterone system the cornerstone of therapy for systolic heart failure. Eur J Heart Fail. 2011;13:929\u201336.","journal-title":"Eur J Heart Fail"},{"key":"6565_CR14","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1093\/eurjhf\/hfr015","volume":"13","author":"JG Cleland","year":"2011","unstructured":"Cleland JG, Coletta AP, Buga L, et al. Clinical trials update from the American heart association meeting 2010: EMPHASIS-HF, RAFT, TIM-HF, Tele-HF, ASCEND-HF, ROCKET-AF, and PROTECT. Eur J Heart Fail. 2011;13:460\u20135.","journal-title":"Eur J Heart Fail"},{"key":"6565_CR15","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1097\/01.hjh.0000165623.72310.dd","volume":"23","author":"V Dzau","year":"2005","unstructured":"Dzau V. The cardiovascular continuum and renin-angiotensin-aldosterone system blockade. J Hyperten Suppl: Off J Int Soc Hypertens. 2005;23:S9\u201317.","journal-title":"J Hyperten Suppl: Off J Int Soc Hypertens"},{"key":"6565_CR16","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1016\/j.jacc.2010.02.025","volume":"55","author":"A Maisel","year":"2010","unstructured":"Maisel A, Mueller C, Nowak R, et al. Mid-region pro-hormone markers for diagnosis and prognosis in acute dyspnea: results from the BACH (biomarkers in acute heart failure) trial. J Am Coll Cardiol. 2010;55:2062\u201376.","journal-title":"J Am Coll Cardiol"},{"key":"6565_CR17","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1161\/CIRCULATIONAHA.107.696906","volume":"116","author":"SD Solomon","year":"2007","unstructured":"Solomon SD, Dobson J, Pocock S, et al. Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure. Circ. 2007;116:1482\u20137.","journal-title":"Circ"},{"key":"6565_CR18","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/S0002-8703(99)70250-4","volume":"138","author":"CM O\u2019Connor","year":"1999","unstructured":"O\u2019Connor CM, Gattis WA, Uretsky BF, et al. Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: insights from the Flolan International Randomized Survival Trial (FIRST). Am Heart J. 1999;138:78\u201386.","journal-title":"Am Heart J"},{"key":"6565_CR19","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/S0735-1097(01)01818-6","volume":"39","author":"MA Silver","year":"2002","unstructured":"Silver MA, Horton DP, Ghali JK, Elkayam U. Effect of nesiritide versus dobutamine on short-term outcomes in the treatment of patients with acutely decompensated heart failure. J Am Coll Cardiol. 2002;39:798\u2013803.","journal-title":"J Am Coll Cardiol"},{"key":"6565_CR20","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1001\/jama.2013.282190","volume":"310","author":"HH Chen","year":"2013","unstructured":"Chen HH, Anstrom KJ, Givertz MM, et al. Low-dose dopamine or low-dose nesiritide in acute heart failure with renal dysfunction: the ROSE acute heart failure randomized trial. Jama. 2013;310:2533\u201343.","journal-title":"Jama"},{"key":"6565_CR21","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.ahj.2008.07.031","volume":"157","author":"AF Hernandez","year":"2009","unstructured":"Hernandez AF, O\u2019Connor CM, Starling RC, et al. Rationale and design of the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure Trial (ASCEND-HF). Am Heart J. 2009;157:271\u20137.","journal-title":"Am Heart J"},{"key":"6565_CR22","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1253\/circj.CJ-12-1618","volume":"77","author":"R Nagai","year":"2013","unstructured":"Nagai R, Kinugawa K, Inoue H, et al. Urgent management of rapid heart rate in patients with atrial fibrillation\/flutter and left ventricular dysfunction: comparison of the ultra-short-acting beta1-selective blocker landiolol with digoxin (J-Land Study). Circ J: Off J Jpn Circ Soc. 2013;77:908\u201316.","journal-title":"Circ J: Off J Jpn Circ Soc"},{"key":"6565_CR23","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1093\/eurheartj\/ehu164","volume":"35","author":"G Montalescot","year":"2014","unstructured":"Montalescot G, Pitt B, de Sa Lopez E, et al. Early eplerenone treatment in patients with acute ST-elevation myocardial infarction without heart failure: the randomized double-blind reminder study. Eur Heart J. 2014;35:2295\u2013302.","journal-title":"Eur Heart J"},{"key":"6565_CR24","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","volume":"370","author":"B Pitt","year":"2014","unstructured":"Pitt B, Pfeffer MA, Assmann SF, et al. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med. 2014;370:1383\u201392.","journal-title":"N Engl J Med"},{"key":"6565_CR25","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1016\/S0140-6736(07)61634-1","volume":"370","author":"M Kitakaze","year":"2007","unstructured":"Kitakaze M, Asakura M, Kim J, et al. Human atrial natriuretic peptide and nicorandil as adjuncts to reperfusion treatment for acute myocardial infarction (J-WIND): two randomised trials. Lancet. 2007;370:1483\u201393.","journal-title":"Lancet"}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-014-6565-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10557-014-6565-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-014-6565-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,30]],"date-time":"2019-05-30T13:28:21Z","timestamp":1559222901000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10557-014-6565-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1,8]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,4]]}},"alternative-id":["6565"],"URL":"https:\/\/doi.org\/10.1007\/s10557-014-6565-2","relation":{},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"value":"0920-3206","type":"print"},{"value":"1573-7241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,1,8]]}}}